Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer

被引:23
作者
Kavanagh, John J. [2 ]
Levenback, Charles F. [2 ]
Ramirez, Pedro T. [2 ]
Wolf, Judith L. [2 ]
Moore, Carla L. [2 ]
Jones, Marsha R. [1 ]
Meng, Lisa [1 ]
Brown, Gail L. [1 ]
Bast, Robert C., Jr. [2 ]
机构
[1] Telik Inc, Palo Alto, CA USA
[2] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA
关键词
GLUTATHIONE-S-TRANSFERASE; CARCINOMA; TOPOTECAN; RECURRENT; EFFICACY; PRODRUG; TLK286; TER286;
D O I
10.1186/1756-8722-3-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin (PLD) in patients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m(2) in combination with PLD at 50 mg/m(2), intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response rate (ORR) and progression-free survival (PFS). Results: Canfosfamide plus PLD combination therapy was administered at 960/50 mg/m(2), respectively. Thirty-nine patients received a median number of 4 cycles (range 1.0-18.0). The ORR was 27.8% (95% CI, 14.2-45.2) with a disease stabilization rate of 80.6% (95% CI, 64.0-91.8) in the evaluable population. The CA-125 marker responses correlated with the radiological findings of complete response or partial response. The median PFS was 6.0 months (95% CI, 4.2-7.9) and median survival was 17.8 months. The combination was well tolerated. Myelosuppression was managed with dose reductions and growth factor support. Grade 3 febrile neutropenia was observed in 2 patients (5.1%). Non-hematologic adverse events occurred at the expected frequency and grade for each drug alone, with no unexpected or cumulative toxicities. Conclusions: Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian cancer. A randomized phase 3 study was conducted based on this supportive phase 2 study.
引用
收藏
页数:11
相关论文
共 33 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]  
Ban N, 1996, CANCER RES, V56, P3577
[3]   Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis [J].
Bristow, RE ;
Tomacruz, RS ;
Armstrong, DK ;
Trimble, EL ;
Montz, FJ .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1248-1259
[4]   2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004) [J].
du Bois, A ;
Quinn, M ;
Thigpen, T ;
Vermorken, J ;
Avall-Lundqvist, E ;
Bookman, M ;
Bowtell, D ;
Brady, M ;
Casado, A ;
Cervantes, A ;
Eisenhauer, E ;
Friedlaender, M ;
Fujiwara, K ;
Grenman, S ;
Guastalla, JP ;
Harper, P ;
Hogberg, T ;
Kaye, S ;
Kitchener, H ;
Kristensen, G ;
Mannel, R ;
Meier, W ;
Miller, B ;
Neijt, JP ;
Oza, A ;
Ozols, R ;
Parmar, M ;
Pecorelli, S ;
Pfisterer, J ;
Poveda, A ;
Provencher, D ;
Pujade-Lauraine, E ;
Randall, M ;
Rochon, J ;
Rustin, G ;
Sagae, S ;
Stehman, F ;
Stuart, G ;
Trimble, E ;
Vasey, P ;
Vergote, I ;
Verheijen, R ;
Wagner, U .
ANNALS OF ONCOLOGY, 2005, 16 :7-12
[5]  
Gate Laurent, 2001, Expert Opin Ther Targets, V5, P477
[6]   Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer [J].
Gordon, AN ;
Tonda, M ;
Sun, S ;
Rackoff, W .
GYNECOLOGIC ONCOLOGY, 2004, 95 (01) :1-8
[7]   Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan [J].
Gordon, AN ;
Fleagle, JT ;
Guthrie, D ;
Parkin, DE ;
Gore, ME ;
Lacave, AJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) :3312-3322
[8]   Activity of TER286 against human tumor colony-forming units [J].
Izbicka, E ;
Lawrence, R ;
Cerna, C ;
VonHoff, DD ;
Sanderson, PE .
ANTI-CANCER DRUGS, 1997, 8 (04) :345-348
[9]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[10]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481